# Strategies for Preventing Healthcare-Associated MDRO infections in Hong Kong










#### **Health Facts of Hong Kong**

#### 2017 Edition

#### Health Facilities (End 2016)

| Number of Public Hospitals and Institutions under Hospital Authority | 42     |
|--|--------|
| Number of Private Hospitals  | 11     |
| Number of Nursing Homes  | 63     |
| Number of Hospitals under Correctional Institutions                  | 21     |
| Number of Hospital Beds in Hospitals in Hospital Authority           | 28 126 |
| Number of Hospital Beds in Private Hospitals                         | 4 226  |
| Number of Hospital Beds in Nursing Homes                             | 5 858  |
| Number of Hospital Beds in Correctional Institutions                 | 880    |

#### Organization chart of the Centre for Health Protection



VOLUME 8, NUMBER 16 JUL 24 - AUG 6, 2011



Protecting Hong Kong's health



#### Feature:

Prevalence survey of infections in public hospitals 2010

Local situation of adenovirus activity





# Prevalence survey of infections in public hospitals 2010

Table 1 - Prevalence of infections.

| Prevalence | Overall Infection<br>% (95% C.I.) | CAI<br>% (95% C.I.) | HAI<br>% (95% C.I.) | OHAI<br>% (95% C.I.) |
|------------|-----------------------------------|---------------------|---------------------|----------------------|
| 2010       | 15.0 (14.5-15.5)                  | 11.9 (11.5-12.4)    | 2.7 (2.5-2.9)       | 0.5 (0.4-0.6)        |
| 2007       | 15.2 (14.7-15.7)                  | 11.4 (11.0-11.8)    | 3.2 (2.9-3.4)       | 0.8 (0.7-0.9)        |




Figure 3 - Prevalence of systemic antimicrobial use by hospital group.

The most common systemic antimicrobials used were **augmentin** (11.8%), followed by **cefuroxime** (2.7%) and **levofloxacin** (2.4%). The pattern was similar to 2007. The overall prevalence of systemic antimicrobial use was **higher in 2010** compared to 2007 (26.6%; 95% C.I.: 26.0%-27.2%)

**Group 1** – general acute hospitals

**Group 2** – hospitals with mixture of acute/ non-acute beds;

**Group 3** – hospitals with non-acute/infirmary beds

**Group 4** – psychiatric hospitals

**Group 5** – acute hospitals of special nature.

### Infection Control Challenges and Opportunities

IN

## CONTROLLING OF MDRO

# Challenges and Opportunities

- Prioritize MDRO
- Modify Isolation Facilities
- Improve Environmental Cleaning





Enter search keyword(s)

Hot searches: Enterovirus, Conjunctivitis, Hand, Foot and Mouth Disease, Chickenpox, Legionnaires' disease

**Health Topics** Others About Recommendations Resources **Statistics** Media Room

#### **Health Topics**



♠ Home > Health Topics > Control of Multi-Drug Resistant Organisms (MDROs)

#### Communicable Diseases

Non-Communicable Diseases and Healthy Living

Healthy Life Course

Organ Donation

Travel Health

Health and Hygiene

Control of Multi-Drug Resistant Organisms (MDROs)

Poisoning

#### Control of Multi-Drug Resistant Organisms (MDROs)







#### Information on MDROs

- 1. Health Education Pamphlet: Multi-Drug Resistant Organisms (MDROs)
- 2. e-Resources Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Infection

#### Safe Use of Antibiotics

- 1. Proper use of antibiotics -
- 2. Safe Use of Antibiotics
- 3. Health Education Pamphlet: Prevent Antimicrobial Resistance

#### Hand Hygiene

Proper hand hygiene







Business & Workplace

< Back



#### MDRO in HA hospitals Hong Kong

|   | 2012                  | 2013  | 2014                 | 2015             | Change   |          |
|---|-----------------------|-------|----------------------|------------------|----------|----------|
| MRSA / all S. aureus  | 43.6%                 | 46.3% | 45.7%                | 46.1%            | <b>→</b> |          |
| MRSA BSI per 1,000 acute  | Overall               | 0.138 | 0.146                | 0.143            | 0.146    | <b>→</b> |
| bed days  | ≥ 2 days of admission | 0.059 | 0.062                | 0.059            | 0.057    | <b>→</b> |
| VRSA  | 0%                    | 0%    | 0%                   | 0%               | <b>→</b> |          |
| VRE   |                       | 0.34% | 1.26%                | 0.74%            | 0.25%    | <b>4</b> |
| ESBL producing Enterobacteria ( <i>E.coli</i> and <i>Klebsiella</i> spp. only |                       | 24.3% | 23.9%                | 23.3%            | 23.2%    | <b>→</b> |
| CRE/CPE Carbapenemase pre<br>Enterobactericeae (E.coli & Klaisolates)         | 36                    | 33    | <b>108</b> (105,993) | 132<br>(110,858) | 1        |          |
| MDRA  | 10.4%                 | 18.6% | 24.9%                | 15.9%            | 7        |          |
| MRPA  |                       | 0.07% | 0.09%                | 0.06%            | 0.02%    | 7        |

#### **MDRO** in **HA** hospitals

|  | 2014  | 2015  | 2016  | 2017  | Change   |
|--|-------|-------|-------|-------|----------|
| MRSA / all S. aureus   | 45.7% | 46.1% | 43.5% | 43.1% | 2        |
| MRSA BSI per 1,000 acute bed days  | 0.143 | 0.146 | 0.158 | 0.144 | <b>→</b> |
| VRSA   | 0%    | 0%    | 0%    | 0%    | none     |
| VRE  | 0.74% | 0.25% | 0.18% | 0.15% | 7        |
| ESBL producing Enterobacteriaceae ( <i>E.coli</i> and <i>Klebsiella</i> spp. only) | 23.3% | 23.2% | 22.4% | 22.0% | 2        |
| CPE Carbapenemase producing Enterobacteriaceae (E.coli & Klebs total isolates)     | 0.10% | 0.12% | 0.30% | 0.40% | 1        |
| MDRA   | 24.9% | 15.9% | 11.7% | 8.6%  | <b>3</b> |
| MRPA   | 0.06% | 0.02% | 0.02% | 0.06% | <b>→</b> |

| Year                                | •                 | 202      | 11  | 2012     |    | 20            | 13              | 201     | 4        | 20           | 15    | 2016      |    | 2017                      |     |
|-------------------------------------|-------------------|----------|-----|----------|----|---------------|-----------------|---------|----------|--------------|-------|-----------|----|---------------------------|-----|
| No of new                           | cases             | 19       | Э   | 36       |    | 3             | 33              |         | 108      |              | 34    | 340       |    | 473                       |     |
| Imported                            | l case            | 10 (53%) |     | 27 (75%) |    | 26 (7         | 26 (79%)        |         | 48 (44%) |              | 31%)  | 79 (23%)  |    | 127 (27%)                 |     |
| Imported                            | from:             | China    | 9   | China    | 23 | China         | 16              | China   | 42       | China        | 31    | China     | 63 | China                     | 101 |
| Hospitaliz                          | ation             | USA      | 1   | Thailand | 2  | India         | 4               | India   | 4        | India        | 6     | India     | 7  | India                     | 8   |
| history ou                          | utside            |          |     | Taiwan   | 1  | Pakistan      | 2               | Vietnam | 1        | Nepal        | 3     | Nepal     | 2  | Thailand                  | 5   |
| HK (Since 1                         | ce 1              |          |     | Burma    | 1  | Indonesi<br>a | 1               | Germany | 1        | Thailan<br>d | 1     | Vietnam   | 2  | Vietnam                   | 3   |
| October 2016, the criteria has been |                   |          |     |          |    | Cambodi<br>a  | 1               |         |          |              |       | Pakistan  | 2  | America                   | 1   |
| extended f                          |                   |          |     |          |    | Korea         | 1               |         |          |              |       | Indonesia | 1  | Bangladesh                | 1   |
| months t                            | to 12             |          |     |          |    | Thailand      | 1               |         |          |              |       | Bail      | 1  | Cambodia                  | 1   |
| month                               | ıs)               |          |     |          |    |               |                 |         |          |              |       | Cambodia  | 1  | Nepal                     | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | Pakistan                  | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | Singapore/Kuala<br>lumpur | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | Spain                     | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | Taiwan                    | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | UK/India                  | 1   |
|                                     |                   |          |     |          |    |               |                 |         |          |              |       |           |    | Ukraine                   | 1   |
|                                     | Clinical specimen |          | 7%) | 13 (36%  | %) | 3 (9          | <del>)</del> %) | 11 (11  | %)       | 21* (        | (15%) | 45 (13%   | 6) | 46 (10%)                  |     |
| specimen Scr                        | reening           | 10 (5    | 3%) | 23 (64%  | %) | 30 (9         | 91%)            | 97 (89  | %)       | 114*         | (85%) | 295 (87%) |    | 427 (90%)                 |     |

#### **CPE Statistic**

|                    | Year                     |                | 20                      | 11      | 20                  | 12    | 2013                       |     | 201                                      | 4          | 201   | 15                             | 2016  | 5                       | 2017                     | (1Q)       | 2017 (2              | Q)  |
|--------------------|--------------------------|----------------|-------------------------|---------|---------------------|-------|----------------------------|-----|--|------------|---|--------------------------------|---|-------------------------|--------------------------|------------|----------------------|-----|
| No o               | f new ca                 | ises           | 19                      | 9       | 3                   | 6     | 33                         |     | 10                                       | 8          | 13  | 4                              | 340   |                         | 9                        | 6          | 85                   |     |
| Imp                | orted ca                 | ise            | 10 (52                  | 2.6%)   | 27 (7               | 75%)  | 26 (78.7                   | 9%) | 48 (4                                    | 4%)        | 41 (30  | ).6%)                          | 79 (58.                                       | 6%)                     | 15 (19                   | 5.8%)      | 31 (36.4             | 1%) |
| Imp                | orted fro                | m:             | China                   | 9       | China               | 23    | China                      | 16  | China                                    | 42         | China   | 31                             | China   | 63                      | China                    | 11         | China                | 24  |
|                    |                          |                | USA                     | 1       | Thailand            | 2     | India                      | 4   | India                                    | 4          | India   | 6                              | India   | 7                       | Thailand                 | 2          | Thailand             | 2   |
| Hospita            | lization                 | history        |                         |         | Taiwan              | 1     | Pakistan                   | 2   | Vietnam                                  | 1          | Nepal   | 3                              | Nepal   | 2                       | India                    | 1          | India                | 2   |
|                    | le HK (Si                |                |                         |         | Burma               | 1     | Indonesia                  | 1   | Germany                                  | 1          | Thailand  | 1                              | Vietnam                                       | 2                       | Bangladesh               | 1          | UK & India           | 1   |
| October 2          |                          |                |                         |         |                     |       | Cambodia                   | 1   |  |            |   |                                | Pakistan                                      | 2                       |                          |            | Spain                | 1   |
| has been           |                          |                |                         |         |                     |       | Korea                      | 1   | 1  |            |   |                                | Indonesia                                     | 1                       |                          |            | Ukraine              | 1   |
| 6 month            | s to 12 n                | nonths)        |                         |         |                     |       | Thailand                   | 1   |  |            |   |                                | Bail  | 1                       |                          |            |                      |     |
|                    |                          |                |                         |         |                     |       |                            |     |  |            |   |                                | Cambodia                                      | 1                       |                          |            |                      |     |
|                    |                          | Sterile        | 1 b                     | ile     | C                   | )     | 0                          |     | 2 (1 blood                               | d, 1 bile) | 1 (periton  | eal swab)                      | 6 (3 blood,<br>hydrosalpir                    |                         | C                        | 0          | 1 bloo               | d   |
|                    |                          |                | 8                       | 3       | 1                   | 3     | 3                          |     | 9  |            | 20  | )*                             | 39  |                         | 8                        | 3          | 9                    |     |
| Type of<br>specime | Clinical<br>specime<br>n | Non<br>sterile | (3 uri<br>sputum<br>swa | , 1 pus | (8 uri<br>sputum, 2 |       | (MSU, CSU,<br>abscess wall |     | (5 CSI<br>sputum/<br>thigh tis<br>knee w | ETA, 1     | (10 uri<br>sputum, 5<br>1 tisso<br>peritonea<br>fluid, 1 po | wound,<br>ue, 1<br>Il dialysis | (26 urin<br>TA/ETA/Spi<br>tubal drain<br>woun | utum, 1<br>fluid, 4     | stool, 1 p<br>dialysis f |            | (7 urine<br>ETA/Sput | -   |
|                    | Scree                    | ening          | 10 (52                  | 2.6%)   | 23 (63              | 3.9%) | 30 (90.9                   | )%) | 97 (8                                    | 9%)        | 114* (8   | 5.07%)                         | 295# (86                                      | 295# (86.8%) 88 (91.7%) |                          | 75 (88.2%) |                      |     |
|                    | NE                       | M              | 2                       |         | 1                   |       | 18                         |     | 48                                       |            | 10  |                                | 190   |                         |                          | .7         | 60                   |     |
|                    | KI                       | PC             | 4                       |         | 7                   |       | 7                          |     | 36                                       |            | 19  |                                | 52  |                         | 3                        | 4          | 9                    |     |
|                    |                          | ΝI             | 1                       |         | 1                   |       | 1                          |     | 1  |            | 0   |                                | 5   |                         |                          | 1          | 2                    |     |
|                    |                          | 1P             | 10                      |         | 1                   |       | 4                          |     | 11                                       |            | 9   |                                | 67  |                         | 8                        |            | 7                    |     |
| PCR                |                          | M<br>KA        | 1                       |         | 1                   |       | 0                          |     | 0  |            | 1   |                                | 0<br>21                                       |                         | (                        |            | 0<br>5               |     |
| result             |                          | HMP            | 1                       |         | 0                   |       | 1                          |     | 3  |            | 0   |                                | 0   |                         |                          | 5<br>n     | 0                    |     |
|                    |                          | +OXA           | 0                       |         | 2                   |       | 0                          |     | 5  |            | 1   |                                | 3   |                         |                          |            | 2                    |     |
|                    |                          | HMP            | 0                       |         |                     |       | 2                          |     | 3  |            | 2   |                                | 0   |                         |                          |            | 0                    |     |
|                    | NDM                      | + IMI          | o                       | )       | C                   | )     | 0                          |     | 0  |            | 0   | )                              | 1   |                         | (                        | 0          | 0                    |     |
|                    | OXA -                    | + IMP          | O                       | )       | C                   | )     | 0                          |     | 0  |            | 0   | )                              | 1   |                         | (                        | 0          | 0                    |     |
|                    |                          | )              | 2                       |         | 3                   |       | 1                          |     | 1  |            | 0   |                                | 8   |                         |                          | 2          | 2                    |     |
|                    | 1-                       |                | 1                       |         | 2                   |       | 2                          |     | 0  |            | 1   |                                | 4   |                         |                          | 2          | 3                    |     |
|                    |                          | 14             | 0                       |         | 0                   |       | 2                          |     | 1  |            | 2   |                                | 2   |                         |                          | 0          | 1                    |     |
|                    | 15-                      |                | _                       | 0 0     |                     |       | 0                          |     | 3  |            | 7   |                                | 4<br>11                                       |                         |                          | 3          | 4<br>7               |     |
| Age                |                          | -34<br>-44     | 0                       |         | 2                   |       | 3<br>1                     |     | 3 9                                      |            | 12  |                                | 26  |                         |                          | 5<br>8     | 8                    |     |
|                    |                          | -44<br>-54     | 1                       |         | 3                   |       | 4                          |     | 11                                       |            | 18  |                                | 32  |                         |                          | 4          | 8                    |     |
|                    |                          | -64            | 3                       |         | 8                   |       | 4                          |     | 23                                       |            | 24  |                                | 53  |                         |                          | .0         | 7                    |     |
|                    |                          | -80            | 7                       |         | 9                   |       | 8                          |     | 40                                       |            | 34  |                                | 106   |                         |                          | 6          | 24                   |     |
|                    | >=                       |                | 4                       | 1       | 8                   |       | 8                          |     | 17                                       |            | 32  |                                | 94  |                         |                          | 5          | 21                   |     |

Data Source: Hospitals reported to CICO office \*1 patient had positive results in both clinical and screening specimens

To show the PCR typing

1. NDM

2. KPC

3. IMI

"Usually accepted that eradication would be unlikely in the highly endemic setting"

< 20 cases 100% elimination

20-39 cases 79% elimination

>39 cases 10% elimination

Marshall et al, JHI 2004:56:253

Boyce JM: ICHE 1991:12:36

Still we should try to lower the incidence...

#### Overcrowding in Hong Kong Public Hospital

Influenza Winter Peak 2018 occupancy of 120-150% - camp beds





#### Search and Destroy for Low prevalent MDRO



#### **Isolation Policies in Hospital Authority – Hong Kong**


|                                     |         |                  | •                |         |                  | 0                      |                     |
|-------------------------------------|---------|------------------|------------------|---------|------------------|------------------------|---------------------|
| IC tactics                          | MRSA    | VISA/<br>VRSA    | VRE ESBL CRE     |         | CRE              | CRAB/<br>MDRA          | CRPA/<br>MRPA       |
| Single room                         | No      | Yes              | Yes              | No      | Yes              | If available<br>(MDRA) | Yes<br>(MRPA-XDR)   |
| PPE, HH,<br>EnH, Deq                | нн      | Yes              | Yes              | нн      | Yes              | Yes                    | Yes                 |
| CMS alert                           | No      | Yes              | Yes              | No      | Yes              | MDRA                   | Yes                 |
| Discharge to RCHE                   | Allowed | 2 -ve<br>culture | 2 -ve<br>culture | Allowed | 2 -ve<br>culture | Allowed                | MRPA: 2 -ve culture |
| Send isolate<br>to reference<br>lab | No      | Yes              | Yes              | No      | Yes              | No                     | No                  |
| Notify Dept<br>Health               | No      | Yes              | Yes              | No      | No               | No                     | MRPA: Yes           |

#### Isolation for ALL MDRO in Private Hospitals



#### Challenges in isolation facilities

- Not enough single room isolation
- Increase manpower when patients are nursed in single room



Layout of general patient ward





Resolution: Single cohort (Specific MDRO patients)

Group cohort (patient with same diagnosis)

Single cohort ante room - Existing site constraint issue



Resolution: Shared ante room with interlocking doors


#### **MDRO** in **HA** hospitals


|  | 2014  | 2015  | 2016  | 2017  | Change   |
|--|-------|-------|-------|-------|----------|
| MRSA / all S. aureus   | 45.7% | 46.1% | 43.5% | 43.1% | 7        |
| MRSA BSI per 1,000 acute bed days  | 0.143 | 0.146 | 0.158 | 0.144 | <b>→</b> |
| VRSA   | 0%    | 0%    | 0%    | 0%    | none     |
| VRE  | 0.74% | 0.25% | 0.18% | 0.15% | 4        |
| ESBL producing Enterobacteriaceae ( <i>E.coli</i> and <i>Klebsiella</i> spp. only)   | 23.3% | 23.2% | 22.4% | 22.0% | 7        |
| CPE Carbapenemase producing<br>Enterobacteriaceae (E.coli & Klebs total<br>isolates) | 0.10% | 0.12% | 0.30% | 0.40% | 1        |
| MDRA   | 24.9% | 15.9% | 11.7% | 8.6%  | 4        |
| MRPA   | 0.06% | 0.02% | 0.02% | 0.06% | <b>→</b> |

#### **Isolation Policies in Hospital Authority – Hong Kong**


|                                     |         |                  | •                |         |                  | 0                      |                     |
|-------------------------------------|---------|------------------|------------------|---------|------------------|------------------------|---------------------|
| IC tactics                          | MRSA    | VISA/<br>VRSA    | VRE              | ESBL    | CRE              | CRAB/<br>MDRA          | CRPA/<br>MRPA       |
| Single room                         | No      | Yes              | Yes              | No      | Yes              | If available<br>(MDRA) | Yes<br>(MRPA-XDR)   |
| PPE, HH,<br>EnH, Deq                | нн      | Yes              | Yes              | нн      | Yes              | Yes                    | Yes                 |
| CMS alert                           | No      | Yes              | Yes              | No      | Yes              | MDRA                   | Yes                 |
| Discharge to RCHE                   | Allowed | 2 -ve<br>culture | 2 -ve<br>culture | Allowed | 2 -ve<br>culture | Allowed                | MRPA: 2 -ve culture |
| Send isolate<br>to reference<br>lab | No      | Yes              | Yes              | No      | Yes              | No                     | No                  |
| Notify Dept<br>Health               | No      | Yes              | Yes              | No      | No               | No                     | MRPA: Yes           |

# MDRO Cubicle









- 1.Beds separated by 1 m apart
- 2. Sufficient supply of PPEs
- 3.Alcohol hand rub at each bedside
  4.Individual patient care items –BP cuff, stet
- 5. Cohort same MDRO in one room or cubicle





Alcohol hand rub




Nurses station is a clean zone. Medical charts stay here. No gowns or gloves allowed. Mask not really needed if not going in to see patients.

# Challenges and Opportunities

Environmental cleaning

Using reusable wash clothes -spreading MDRO and OSH concern

### New VRE cases in HA hospitals



# Cleansing of the Environment

| HA guideline Hong Kong  | CDC                          | wно               | AUS  | NHS  | Canada  |
|---|------------------------------|-------------------|--|--|---|
| when the environment is visibly soiled or contaminated;                             | <b>√</b>                     | ✓                 | ✓  | ✓  | ✓   |
| General housekeeping surfaces - according to housekeeping cleaning schedule         |                              |                   | ✓  | <b>✓</b>                                     | ✓   |
| HTA in General clinical area - cleaned with detergent and water at least once daily | more<br>frequent<br>schedule | <b>√</b>          | <b>√</b>                                     | <b>✓</b>                                     | ✓   |
| HTA in Contact Precautions - cleaned and disinfected at least twice daily.          | more<br>frequent<br>schedule | At least<br>daily | (Base on<br>Risk level,<br>e.g.<br>Outbreak) | (Base on<br>Risk level,<br>e.g. ICU,<br>AED) | (Base on Risk<br>level, e.g. VRE,<br>C. diff) |

#### Meeting the challenge of VRE outbreak

Improvement on environmental cleaning

From reusable wash clothes disposable jay clothes

From disposable jay clothes single use disinfectant wipes

Plus non-touch environmental disinfection machines

#### Manual Cleaning:


- Standardize cleaning protocols in clinical areas
- Designated team for EH
- Training
- Onsite coaching and return demonstration regular monitoring of cleanliness
- Use of dedicated equipment
- Disposable wipe
- 2:1 disinfectants

Bathrooms, washrooms, showers, toilets, basins and bathroom floors

General areas including wards, departments, offices and basins in public areas

Catering departments, ward kitchen areas and patient food service at ward level

Isolation areas








Disposable Wipes


# Wipes

Cotton, Disposable, Microfiber, Nonwoven Spunlace

Wipe should have sufficient wetness to achieve the disinfectant contact time. Discontinue use of a disposable wipe if it no longer leaves the surface visibly wet for  $\geq$  1min



# New technology for the control of MDROs





Kowloon Central Cluster

Hospital Authority

Queen Elizabeth Hospital

Hydrogen Peroxide Vaporization (HPV) Standard Operation Procedure

| KCC/QE/ICT/ICT/OP/0005             |                                   |                          |  |  |  |  |  |
|------------------------------------|-----------------------------------|--------------------------|--|--|--|--|--|
| Infection Control Team             |                                   |                          |  |  |  |  |  |
| Operating Procedure Version MAY 13 |                                   |                          |  |  |  |  |  |
|                                    | Document Owner: S Y LEE, SNM(ICT) |                          |  |  |  |  |  |
|                                    | Signature:                        |                          |  |  |  |  |  |
|                                    | Approval C                        | Officer: DR. NC TS       | ANG, CICO, KCC   |  |  |  |  |
|                                    | Signature:                        |                          |  |  |  |  |  |
|                                    |                                   | Signature:<br>Approval C | Operating Procedure Version  Document Owner: S Y LEE, S Signature:  Approval Officer: DR. NC TS. |  |  |  |  |





#### **MDRO** in **HA** hospitals

|  | 2014  | 2015  | 2016  | 2017  | Change   |
|--|-------|-------|-------|-------|----------|
| MRSA / all S. aureus   | 45.7% | 46.1% | 43.5% | 43.1% | <b>4</b> |
| MRSA BSI per 1,000 acute bed days  | 0.143 | 0.146 | 0.158 | 0.144 | <b>→</b> |
| VRSA   | 0%    | 0%    | 0%    | 0%    | none     |
| VRE 2013 - 1.26%   | 0.74% | 0.25% | 0.18% | 0.15% | 7        |
| ESBL producing Enterobacteriaceae ( <i>E.coli</i> and <i>Klebsiella</i> spp. only)   | 23.3% | 23.2% | 22.4% | 22.0% | 7        |
| CPE Carbapenemase producing<br>Enterobacteriaceae (E.coli & Klebs total<br>isolates) | 0.10% | 0.12% | 0.30% | 0.40% | 1        |
| MDRA   | 24.9% | 15.9% | 11.7% | 8.6%  | 7        |
| MRPA   | 0.06% | 0.02% | 0.02% | 0.06% | <b>→</b> |

#### Turning Challenges to Opportunities

- Difficulties in controlling MDRO
  - Prioritize MDRO for contact precautions
  - Emerging MDRO implement "search and destroy"
- Coping with insufficient isolation facilities
  - Prioritize emerging MDRO for contact precautions
  - Cohorting SAME mdro with special droplet precautions
- Ineffective environmental cleaning
  - Convert old practice to most up-to-date practices
  - Changed to disposable wipes and non-touch environment disinfection machine



# Thank You!!